[Interleukin-3: a preclinical study].
Recombinant hemopoietic cytokines play an increasing role in clinical hematology. The present preclinical study describes the biologic spectrum of a novel recombinant human cytokine, interleukin-3 (rhIL-3). In appropriate culture systems it could be demonstrated that interleukin-3 is a potent growth factor for hemopoietic stem cells. RhIL-3 induced, in addition, terminal differentiation of basophilic and eosinophilic granulocytes. Moreover, rhIL-3 was found to be an activation factor for mature blood basophils. Binding studies using radiolabelled rhIL-3 showed that the effects of interleukin-3 are mediated via specific cell surface membrane receptors. The in vivo effects of recombinant interleukin-3 were studied in a primate model (rhesus monkeys). In agreement with in vitro results interleukin-3 caused significant expansion of the functional stem cell pool. Moreover, interleukin-3 induced a marked increase in basophils and eosinophils. As side effects of recombinant interleukin-3 a slight to moderate elevation of plasma histamine levels was observed as well as the appearance of an erythematous exanthem. In summary, our studies provide evidence that IL-3 induces self renewal, growth and differentiation of human hemopoietic stem cells. Clinical indication areas for interleukin-3 obviously represent stem cell transplantation and the treatment of cytopenic disorders. Adverse side effects of this novel cytokine might arise from stimulation of growth and function of "allergic effector cells".